Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$35.53 – $45.77
66% from low
Exchange
BATS
ETF
Borrow rate
10.48%
Hard to borrow
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| BINVBrandes International ETF | $42.30 | -1.01% | $488M | — |
| BUSABrandes U.S. Value ETF | $39.66 | -0.38% | $294M | — |
| DEHPDimensional - Emerging Markets High Profitability ETF | $42.08 | +0.79% | $455M | — |
| DFNLDavis Select Financial ETF | $49.55 | +0.52% | $459M | — |
| KJANInnovator U.S. Small Cap Power Buffer ETF - January | $45.51 |
No company description on file.
No one on the platform currently holds BINV.
No tracked institution reports a position in BINV as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-06-29 | $0.5462 | 2026-06-30 |
| 2026-03-30 | $0.0043 | 2026-03-31 |
| 2025-12-30 | $0.2532 | 2025-12-31 |
| 2025-09-29 | $0.1272 | 2025-09-30 |
| 2025-06-27 | $0.4950 | 2025-06-30 |
| 2025-03-28 | $0.0180 | 2025-03-31 |
| 2024-12-30 | $0.1578 | 2024-12-31 |
| 2024-09-27 | $0.1003 | 2024-09-30 |
| 2024-06-27 | $0.4288 | 2024-06-28 |
| 2024-03-26 | $0.0287 | 2024-03-28 |
No one on the platform has traded BINV yet.
| +0.15% |
| $331M |
| — |
| PALCPacer Lunt Large Cap Multi-Factor Alternator ETF | $58.93 | +2.00% | $229M | — |
| RWXState Street SPDR Dow Jones International Real Estate ETF | $27.19 | +0.18% | $271M | — |
Source: Financial Modeling Prep · peers by sector/industry
| 2023-12-27 | $0.0805 | 2023-12-29 |
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
I found you an Overbought RSI (Relative Strength Index) on the daily chart of 2023 ETF Series Trust - Brandes International ETF. Is that bullish or bearish? $BINV #RsiOverbought #BATS
View on StockTwits ↗I found you an Overbought RSI (Relative Strength Index) on the daily chart of 2023 ETF Series Trust - Brandes International ETF. Is that bullish or bearish? $BINV #RsiOverbought #BATS
View on StockTwits ↗$CASI $BINV CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China https://www.stocktitan.net/news/CASI/casi-pharmaceuticals-report-positive-interim-phase-1-data-for-bi-4imgphl23c8v.html
View on StockTwits ↗$BINV Transgene and BioInvent - First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA® (pembrolizumab) https://www.stocktitan.net/news/BINV/transgene-and-bio-invent-first-patient-treated-in-part-b-of-phase-i-i0pfgkvgmowg.html
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.